A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
复制标题
DOI：
10.1126/scitranslmed.abc3103
复制
发表时间：
2020-09-02
影响因子：
17.1
通讯作者：
van der Werf S
中科院分区：
文献类型：
--
作者：
Grzelak L;Temmam S;Planchais C;Demeret C;Tondeur L;Huon C;Guivel-Benhassine F;Staropoli I;Chazal M;Dufloo J;Planas D;Buchrieser J;Rajah MM;Robinot R;Porrot F;Albert M;Chen KY;Crescenzo-Chaigne B;Donati F;Anna F;Souque P;Gransagne M;Bellalou J;Nowakowski M;Backovic M;Bouadma L;Le Fevre L;Le Hingrat Q;Descamps D;Pourbaix A;Laouénan C;Ghosn J;Yazdanpanah Y;Besombes C;Jolly N;Pellerin-Fernandes S;Cheny O;Ungeheuer MN;Mellon G;Morel P;Rolland S;Rey FA;Behillil S;Enouf V;Lemaitre A;Créach MA;Petres S;Escriou N;Charneau P;Fontanet A;Hoen B;Bruel T;Eloit M;Mouquet H;Schwartz O;van der Werf S
比较不同血清学方法检测重症和轻度新冠肺炎患者血清中抗SARS-CoV-2抗体及其中和活性。感染SARS-CoV-2病毒的人会产生抗体反应，这种反应可能会根据疾病的严重程度而有所不同。Grzelak等人。检测了疫情前491名健康人、51名新冠肺炎患者住院患者、209例症状轻微的新冠肺炎疑似病例以及200名健康献血者的血清样本中抗SARS-CoV-2抗体的含量。作者开发并比较了四种不同的血清学方法的性能，这些方法测量抗体数量和它们的中和活性。这些检测能够对无症状、轻度症状和重度新冠肺炎病例的SARS-CoV-2血清阳性率和抗体谱进行广泛评估。评估无症状和有症状的SARS-CoV-2感染病例的流行率及其不同的抗体反应谱是至关重要的。在这里，我们进行了四种血清学方法的初步研究，以评估SARS-CoV-2大流行前的491名健康人、51名新冠肺炎住院患者、209例症状轻微的新冠肺炎疑似病例和200名健康献血员的血清抗SARS-CoV-2抗体水平。我们使用了两种识别SARS-CoV-2全长核蛋白(N)或三聚体尖峰蛋白(S)胞外结构域的ELISA法。此外，我们还建立了利用流式细胞术识别细胞表面表达的S蛋白的S-Flow方法和通过免疫沉淀识别SARS-CoV-2抗原的荧光素酶免疫沉淀系统(LIPS)方法。我们用四种血清学方法得到了相似的结果。敏感性的差异归因于技术和使用的抗原。抗SARS-CoV-2抗体效价高与中和活性有关，这与传染性SARS-CoV-2或慢病毒-S伪型病毒的中和活性有关。在住院的新冠肺炎患者中，血清转换和病毒中和发生在症状出现后5至14天，证实了之前的研究。32%的轻度症状个体在症状出现后15天内检测到血清阳性，在健康献血者中检测到3%。我们使用的四种抗体检测方法能够广泛评估SARS-CoV-2在一个地区内不同亚群中的血清阳性率和抗体谱。
Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared. Individuals infected with SARS-CoV-2 mount an antibody response that may vary depending on the severity of the disease. Grzelak et al. assessed the amounts of anti–SARS-CoV-2 antibodies in serum samples from 491 healthy individuals before the pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. The authors developed and compared the performance of four different serological assays measuring antibody amounts and their neutralizing activity. The assays enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in asymptomatic, mildly symptomatic, and severe cases of COVID-19. It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti–SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti–SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
登录
查看更多内容
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F
影响因子：
12.4
作者：
Iglesias, Maria Candela;Mollier, Karine;Charneau, Pierre
通讯作者：
Charneau, Pierre
影响因子：
2.2
作者：
Lorin, Valerie;Mouquet, Hugo
通讯作者：
Mouquet, Hugo
影响因子：
5.5
作者：
Kam YW;Kien F;Roberts A;Cheung YC;Lamirande EW;Vogel L;Chu SL;Tse J;Guarner J;Zaki SR;Subbarao K;Peiris M;Nal B;Altmeyer R
通讯作者：
Altmeyer R
SARS-CoV-2 刺突糖蛋白在病毒进入过程中的特征及其与 SARS-CoV 的免疫交叉反应
影响因子：
16.6
作者：
Ou, Xiuyuan;Liu, Yan;Qian, Zhaohui
通讯作者：
Qian, Zhaohui